Microglial Subtypes in Neurodegeneration: Friend vs Foe¶
Analysis ID: SDA-2026-04-02-gap-microglial-subtypes-20260402004119 Date: 2026-04-02 Domain: Neurodegeneration -- Neuroimmunology
Objective¶
Analyze the spectrum of microglial activation states (DAM, homeostatic, inflammatory) and their distinct roles in AD, PD, and ALS. Identify pharmacological targets for shifting microglia toward protective phenotypes.
1. Microglial State Space¶
Define and simulate the five major microglial phenotypes observed in neurodegeneration.
2. t-SNE Visualization of Microglial States¶
3. State Proportions Across Diseases¶
4. Protective vs Harmful Score¶
5. Pharmacological Target Identification¶
6. Hypotheses¶
H1: TREM2 Agonism Is Optimal for AD, Not ALS¶
TREM2 agonists amplify the DAM program, which is already the dominant shift in AD. In ALS, where inflammatory microglia dominate, TREM2 agonism alone is insufficient -- anti-inflammatory co-therapy is needed.
H2: Disease-Specific Microglial Therapeutic Strategies¶
Each neurodegenerative disease has a unique microglial state distribution requiring tailored interventions: AD -> TREM2 agonist, PD -> TGF-b + IL-1b blocker, ALS -> JAK inhibitor + TREM2 agonist.
H3: Interferon-Responsive Microglia as AD Accelerators¶
The IFN-responsive state (IFIT1, ISG15, MX1) emerges in AD and ALS. These cells may respond to endogenous viral reactivation or cytosolic DNA sensing (cGAS-STING). Test: STING inhibitor in 5xFAD mice.
H4: Microglial Depletion-Repopulation as Reset Strategy¶
CSF1R inhibition depletes all microglia. Upon repopulation, microglia return to homeostatic state. This may be a 'hard reset' for chronic neuroinflammation. Test: PLX5622 treatment followed by washout in aged AD mice.
H5: Protective/Harmful Balance as a Biomarker¶
The net protection score distinguishes disease states. CSF biomarkers of microglial state (sTREM2, IL-1b, P2RY12) could serve as a treatment monitoring panel.
Generated by SciDEX Atlas Layer -- https://scidex.ai